Shares of ImmuCell Corporation (ICCC) have declined 7.4% since the company reported its earnings for the second quarter of 2025. This compares unfavorably with the S&P 500 index, which slipped just 0.8% during the same period. Over the past month, ImmuCell stock has dropped 11.5%, while the broader market posted a 1.8% gain, reflecting clear investor caution despite the company’s operational improvements.ImmuCell posted second-quarter revenues of $6.4 million, up 18% from $5.5 million a year earlier. Net in ...